Free Trial
NASDAQ:NPCE

NeuroPace (NPCE) Stock Price, News & Analysis

NeuroPace logo
$11.14 -0.14 (-1.24%)
(As of 11:39 AM ET)

About NeuroPace Stock (NASDAQ:NPCE)

Key Stats

Today's Range
$11.09
$11.45
50-Day Range
$5.90
$11.93
52-Week Range
$5.45
$18.15
Volume
13,940 shs
Average Volume
95,998 shs
Market Capitalization
$332.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.60
Consensus Rating
Moderate Buy

Company Overview

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NeuroPace Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
73rd Percentile Overall Score

NPCE MarketRank™: 

NeuroPace scored higher than 73% of companies evaluated by MarketBeat, and ranked 302nd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    NeuroPace has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    NeuroPace has only been the subject of 1 research reports in the past 90 days.

  • Read more about NeuroPace's stock forecast and price target.
  • Earnings Growth

    Earnings for NeuroPace are expected to grow in the coming year, from ($1.00) to ($0.98) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of NeuroPace is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of NeuroPace is -11.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    NeuroPace has a P/B Ratio of 14.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.12% of the float of NeuroPace has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroPace has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in NeuroPace has recently decreased by 33.68%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    NeuroPace does not currently pay a dividend.

  • Dividend Growth

    NeuroPace does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.12% of the float of NeuroPace has been sold short.
  • Short Interest Ratio / Days to Cover

    NeuroPace has a short interest ratio ("days to cover") of 4.
  • Change versus previous month

    Short interest in NeuroPace has recently decreased by 33.68%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    NeuroPace has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for NeuroPace this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added NeuroPace to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, NeuroPace insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,437,916.00 in company stock.

  • Percentage Held by Insiders

    22.20% of the stock of NeuroPace is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    78.83% of the stock of NeuroPace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about NeuroPace's insider trading history.
Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

NPCE Stock News Headlines

Lake Street Sticks to Its Buy Rating for NeuroPace (NPCE)
Affordable AI Plays: 2 Stocks Under $10 with Huge Potential!
As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.
NeuroPace’s Strong Q3 Performance and Growth Potential Earns Buy Rating
NeuroPace price target lowered to $13 from $15 at Wells Fargo
See More Headlines

NPCE Stock Analysis - Frequently Asked Questions

NeuroPace's stock was trading at $10.31 at the beginning of the year. Since then, NPCE stock has increased by 9.7% and is now trading at $11.31.
View the best growth stocks for 2024 here
.

NeuroPace, Inc. (NASDAQ:NPCE) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. The business had revenue of $21.06 million for the quarter, compared to analysts' expectations of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative trailing twelve-month return on equity of 205.41%.

NeuroPace (NPCE) raised $85 million in an IPO on Thursday, April 22nd 2021. The company issued 5,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

NeuroPace's top institutional shareholders include Geode Capital Management LLC (1.09%), State Street Corp (0.53%), Barclays PLC (0.07%) and Barclays PLC (0.07%). Insiders that own company stock include Ltd Kck, Accelmed Partners Ii LP, Orbimed Advisors Llc, Martha Morrell and Irina Ridley.
View institutional ownership trends
.

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that NeuroPace investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL).

Company Calendar

Last Earnings
11/12/2024
Today
12/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:NPCE
Fax
N/A
Employees
170
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.60
High Stock Price Target
$22.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+29.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-32,960,000.00
Pretax Margin
-36.74%

Debt

Sales & Book Value

Annual Sales
$65.42 million
Book Value
$0.79 per share

Miscellaneous

Free Float
23,222,000
Market Cap
$337.60 million
Optionable
Optionable
Beta
2.05
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:NPCE) was last updated on 12/9/2024 by MarketBeat.com Staff
From Our Partners